International reports of coronavirus disease 2019 (COVID-19)–related severe complications in children began in April 2020 when predominantly healthy children were hospitalized with cardiogenic shock or Kawasaki disease–like presentations temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
1-3 In mid-May 2020, the Centers for Disease Control and Prevention (CDC) published a case definition for multisystem inflammatory syndrome in children (MIS-C) for disease surveillance.
4 Criteria were intentionally broad to facilitate data capture for diagnostic refinement. MIS-C was hypothesized to be mostly postinfectious and distinct from COVID-19 because many patients’ respiratory specimens were SARS-CoV-2 negative and MIS-C peaked after reported COVID-19 cases.
5,6 Cardiovascular complications, such as ventricular dysfunction and coronary artery aneurysms, triggered recommendations for immunomodulatory treatments, including intravenous immunoglobulin (IVIG), corticosteroids, and biologics, and recommendations for intensive cardiac observation.
5-9